1 omly reassigned to either 50 mg or 100 mg of sirukumab.

2                                              Sirukumab, a human monoclonal antibody that selectively

3  including early escape patients switched to sirukumab at week 18] of 294; 194 [66%] of 292 with 50 m

4 tly randomly reassigned at week 24 to either sirukumab dose (crossover).

5 very 4 weeks and 0.21 (0.14-0.29) for 100 mg sirukumab every 2 weeks (both p<0.0001).

6 ry 4 weeks, and 132 (45%) of 292 with 100 mg sirukumab every 2 weeks versus 71 (24%) of 294 with plac

7 umab every 4 weeks, and 41 [14%] with 100 mg sirukumab every 2 weeks).

8 ry 4 weeks; and 207 [71%] of 292 with 100 mg sirukumab every 2 weeks).

9 very 4 weeks and 66 [16%] of 418 with 100 mg sirukumab every 2 weeks).

10 ks, 50 mg sirukumab every 4 weeks, or 100 mg sirukumab every 2 weeks, all given for 52 weeks or less.

11 g sirukumab every 4 weeks, and 292 to 100 mg sirukumab every 2 weeks.

12 acebo were 0.16 (95% CI 0.09-0.23) for 50 mg sirukumab every 4 weeks and 0.21 (0.14-0.29) for 100 mg

13 ion-site erythema (33 [8%] of 416 with 50 mg sirukumab every 4 weeks and 66 [16%] of 418 with 100 mg

14  at week 16 were 117 (40%) of 292 with 50 mg sirukumab every 4 weeks, and 132 (45%) of 292 with 100 m

15 s to treatment: 294 to placebo, 292 to 50 mg sirukumab every 4 weeks, and 292 to 100 mg sirukumab eve

16  (four [1%] with placebo, 22 [8%] with 50 mg sirukumab every 4 weeks, and 41 [14%] with 100 mg siruku

17 ystem to either placebo every 2 weeks, 50 mg sirukumab every 4 weeks, or 100 mg sirukumab every 2 wee

18 week 18] of 294; 194 [66%] of 292 with 50 mg sirukumab every 4 weeks; and 207 [71%] of 292 with 100 m

19 e aimed to assess the efficacy and safety of sirukumab for rheumatoid arthritis in a phase 3 study (S

20 aneous injection; patients assigned to 50 mg sirukumab given every 4 weeks also received a placebo in

21        At week 52, of all patients receiving sirukumab including those reassigned from placebo, the m

22 ological treatments, both dosing regimens of sirukumab were well tolerated and significantly improved